Initial Public Offering and Financing of Biotechnology Start-ups: Evidence from Japan
Yuji Honjo and
No 15-20, IIR Working Paper from Institute of Innovation Research, Hitotsubashi University
This paper explores the initial public offering (IPO) and financing of biotechnology start-ups in Japan. Using a unique data set, we find that biotechnology start-ups initially backed by venture capital (VC) firms and those originating from universities are more likely to go public within a shorter period. Moreover, we examine whether two investment methods used by VC firms?staged financing and syndication?affect the market value of equity at the IPO. The results reveal that these methods do not create a higher value of biotechnology start-ups at the IPO. Furthermore, we provide evidence that the timing of IPOs does not depend on market conditions in the biotechnology industry, whereas the market value of equity tends to depend on market conditions.
Keywords: Biotechnology; Initial public offering; Market value; Staged financing; Start-up; Syndication (search for similar items in EconPapers)
JEL-codes: G32 L65 M13 (search for similar items in EconPapers)
New Economics Papers: this item is included in nep-cfn, nep-ent and nep-ino
References: View references in EconPapers View complete reference list from CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
Journal Article: Initial public offering and financing of biotechnology start-ups: Evidence from Japan (2018)
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:hit:iirwps:15-20
Access Statistics for this paper
More papers in IIR Working Paper from Institute of Innovation Research, Hitotsubashi University Contact information at EDIRC.
Bibliographic data for series maintained by Digital Resources Section, Hitotsubashi University Library ().